Skip to main content

Table 2 Current active trials in HNSCC testing the safety and efficacy of novel drug combinations

From: Genomically personalized therapy in head and neck cancer

Trials Trial phase Drug 1 Drug 2 Pathway 1 Pathway 2 Setting Status
NCT01716416 1 Pazopanib Cetuximab Angiogenesis EGFR Recurrent, metastatic Recruiting
NCT02499120 2 Palbociclib Cetuximab Cell cycle EGFR Plcebo controlled randomized phase II, recurrent, metastatic Recruiting
NCT02101034 1,2 Palbociclib Cetuximab Cell cycle EGFR Recurrent, metastatic Recruiting
NCT01711541 1, 2 Veliparib Chemotherapy DNA repair EGFR Recurrent, metastatic Recruiting
NCT02538627 1 MM-151 MM-121 EGFR ERBB Recurrent, metastatic Recruiting
NCT02501096 1, 2 Pembrolizumab Lenvatinib Immune Angiogenesis Recurrent, metastatic Recruiting
NCT02454179 2 Pembrolizumab ACP-196 Immune Bruton Tyrosine Kinase Recurrent, metastatic Recruiting
NCT02646748 1 Pembrolizumab INCB039110/INCB050465 Immune JAK/PI3K Recurrent, metastatic Recruiting
NCT01468896 1, 2 Recombinant interleukin-2 Cetuximab Immune EGFR Recurrent, metastatic Active, not recruiting
NCT02507154 1, 2 NK cells Cetuximab Immune EGFR Recurrent, metastatic Recruiting
NCT02643550 1, 2 Monalizumab Cetuximab Immune EGFR Recurrent, metastatic Recruiting
NCT02110082 1 Urelumab Cetuximab Immune EGFR Recurrent, metastatic Active, not recruiting
NCT02124850 1 Motolimod/Nivolumab Cetuximab Immune EGFR Stage II-IVA, neoadjuvant Recruiting
NCT02586987 1 MEDI4736 Selumetinib Immune MEK Recurrent, metastatic Recruiting
NCT01871311 1 Nilotinib Cetuximab Kit EGFR Recurrent, metastatic Recruiting
NCT02277197 1 Ficlatuzumab Cetuximab MET EGFR Recurrent, metastatic Recruiting
NCT01332266 1, 2 E7050 Cetuximab MET EGFR Recurrent, metastatic Recruiting
NCT02205398 1 INC280 Cetuximab MET EGFR Recurrent, metastatic Recruiting
NCT01285037 1 LY2801653 Cetuximab MET EGFR Recurrent, metastatic Recruiting
NCT01602315 1b, 2 BYL719 Cetuximab PI3K EGFR Recurrent, metastatic Active, not recruiting
NCT01488318 2 Dasatinib Cetuximab Scr EGFR Recurrent, metastatic Recruiting